Illumina and Labcorp have expanded their collaboration to strengthen precision oncology through wider use of next-generation sequencing (NGS) technologies.

The partnership will focus on improving access to cancer biomarker testing, especially by bringing advanced testing closer to patients. This includes developing distributed testing solutions, generating clinical evidence to support insurance coverage, and creating new diagnostic tests to address unmet needs in cancer care.

Both companies plan to work on advanced research as well as in vitro diagnostic (IVD) tests, including comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS). These efforts are aimed at closing existing gaps in cancer diagnostics and supporting more personalized treatment approaches.

As part of the collaboration, Illumina and Labcorp will explore co-commercialisation of Labcorp’s FDA-authorised liquid biopsy test, PGDx elio plasma focus Dx, alongside Illumina’s FDA-approved TruSight Oncology Comprehensive test for solid tumours. Together, these solutions are expected to expand access to both tissue and liquid biopsy testing across hospitals and community healthcare settings.

The goal is to enable more accurate diagnoses and help identify patients who may benefit from targeted therapies or clinical trials. The combined offering is also expected to support pharmaceutical companies in developing companion diagnostics, which are increasingly important for targeted drug approvals.

According to company executives, the collaboration builds on a long-standing relationship focused on advancing cancer care through innovation and improved access. By combining their expertise, both organisations aim to deliver testing solutions that support faster and more equitable care for patients.

The companies will also continue joint research to demonstrate the clinical value of genomic profiling. In one recent study involving over 7,600 non-small cell lung cancer samples, comprehensive genomic profiling was able to detect clinically relevant variants in more than 72 Percent of cases, including those linked to existing targeted therapies or clinical trials.

Since 2022, Illumina and Labcorp have collaborated on multiple scientific publications, along with several presentations at industry conferences, highlighting their ongoing focus on advancing precision medicine.

Overall, the expanded partnership reflects a broader push to integrate advanced genomics into routine cancer care, making personalised treatment more accessible across different healthcare settings.